
[View Journal Online](#)  
[View Article Online](#)

## Synthesis and antimicrobial activity of new *ent*-kaurene-type diterpenoid derivatives

Andrés Eduardo Márquez-Chacón <sup>1,\*</sup>, Alida Pérez Colmenares <sup>1</sup>, Luis Rojas Fermín † <sup>1</sup>, Rosa Aparicio <sup>1</sup>, Freddy Alejandro Ramos <sup>2</sup>, Alfredo Usubillaga <sup>1</sup> and Ysbelia Obregón <sup>1</sup>

<sup>1</sup> Research Institute, Faculty of Pharmacy and Bioanalysis, University of Los Andes, Mérida, 5101, Venezuela

<sup>2</sup> Department of Chemistry, Faculty of Science, National University of Colombia, Bogotá, 111321, Colombia

\* Corresponding author at: Research Institute, Faculty of Pharmacy and Bioanalysis, University of Los Andes, Mérida, 5101, Venezuela.  
 e-mail: [andresmqch@gmail.com](mailto:andresmqch@gmail.com) (A.E. Márquez-Chacón).

### RESEARCH ARTICLE

### ABSTRACT



doi 10.5155/eurjchem.14.4.478-485.2478

Received: 16 September 2023

Received in revised form: 04 November 2023

Accepted: 12 November 2023

Published online: 31 December 2023

Printed: 31 December 2023

### KEYWORDS

Diterpenes  
 Drug discovery  
 Antifungal agents  
 Antibacterial activity  
*ent*-Kaurene derivatives  
 Structure-activity relationship

This research consists in the synthesis of *ent*-kaurene-type diterpenoid derivatives from the new natural product *ent*-kaur-3-acetoxy-15-ene, to carry out structural modifications on the C<sub>3</sub> carbon of the *ent*-kaurene core by introducing different oxygenated groups, especially esters, in order to probe the structure-activity relationship (SAR) against microorganisms. The structure of the compounds was confirmed by FT-IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, and GC-MS. The antimicrobial activity of the synthesized derivatives was evaluated, *ent*-kaur-3-*O*-(6',7'-bibenzyl-oxy-caffeoyl)-15-ene (4) exhibited activity against all tested microorganisms: *Staphylococcus aureus* (16 mm), *Enterococcus faecalis* (12 mm), *Escherichia coli* (13 mm), *Klebsiella pneumoniae* (10 mm), *Pseudomonas aeruginosa* (8 mm) and *Candida krusei* (10 mm). These results reveal a remarkable structure-activity relationship over the C<sub>3</sub> carbon of the *ent*-kaurene core, where the presence of oxygenated groups such as hydroxyl or alkyl esters enhances activity.

Cite this: *Eur. J. Chem.* 2023, 14(4), 478-485

Journal website: [www.eurjchem.com](http://www.eurjchem.com)

### 1. Introduction

Natural products (NP) and their semi-synthetic analogues have played a vital role in the description and expansion of antimicrobial drugs, especially in the last 20 years [1]. Various terrestrial sources, such as plants, fungi, and lichens, present more than 80% of the described naturally occurring antibiotics. These natural products, together with new synthetic analogues, have confirmed their efficacy as alternatives to antimicrobial agents [2]. In addition, new natural and synthetic compounds have attracted considerable interest in replacing the potency of ineffective antibiotics. Diterpenes are one of the most important classes of NPs, due to their wide range of biological and ecological activities, such as antimicrobial [3], cytotoxicity with relative selectivity for cancer cells [4], antiparasitic [5], anti-HIV activity [6], anti-inflammatory [7], among others. In particular, there is a notable diterpene skeleton in this class: *ent*-kaurenes (Figure 1) [8,9].

*Ent*-kaurene diterpenoids represent an important group of tetracyclic diterpenes that have a long history of research and medical applications in traditional eastern remedies, and have attracted increasing interest since the last century due to their structural diversity and complexity, together with extensive

bioactivity profiles such as antitumor, antibacterial, antiviral, and anti-inflammatory effects [10]. *Ent*-kaurene was first isolated from the essential oil of the leaves of the New Zealand kauri (*Agathis australis* Salisb), a plant locally known as kauri pine [10]. However, plants of the genus *Espeletia* (subtribe Espeletiinae Cuatrec., Asteraceae), popularly known as "frailejón", which grow at an altitude of 2500 m in the northern Andes of South America and are used by high-moorland inhabitants with well-described medicinal attributes, provide an abundant source of natural products *ent*-kauranoid [11,12].




Figure 1. Carbon skeleton of an *ent*-kaurene-type diterpene.

Moreover, compounds with slight structural differences can be observed to show very different biological activities in

several cases [13-16]. It should also be considered that these natural substances can be subjected to chemical modifications by chemical reactions or biotransformations, providing analogues that can be even more active [17,18]. Therefore, this is an interesting way to obtain new active compounds, which is important in the search for new antibiotics and treatments to defeat microbes. Natural products research in this field still represents a good prospect for finding new bioactive structures based on which new less expensive drugs can be developed; in recent decades, the use of additive and/or synergistic combinations of synthetic drugs and phytochemicals has been increasingly encouraged.

Part of the research focuses on the evaluation of biological activities of *ent*-kaurenes [19,20] considering the semi-synthesis approach [19-22], and some interesting previous results obtained in the research group [23], the decision was made to perform a search for active compounds against bacterial and fungal strains by obtaining semi-synthetic derivatives of the new natural product *ent*-kaurene: *ent*-kaur-3-acetoxy-15-ene (1), which was isolated from the extraction of neutral fractions from the leaves of *Espeletia semiglobulata* Cuatrec. (Asteraceae) [23].

*Ent*-kaur-3-acetoxy-15-ene (1) [23] was allowed to react with an excess of LiAlH<sub>4</sub>, as a result of which the hydroxyl derivative was obtained (2), and from its different derivatives were synthesized (3-8). The results of the research on the synthesis, characterization, and antimicrobial activity against some microorganisms of novel *ent*-kaurane-type diterpenoid derivatives are presented here.

## 2. Experimental

### 2.1. Materials and instrumentation

All reagents and solvents were obtained from Sigma-Aldrich, Acros Organics, and Fisher Scientific and used as supplied unless otherwise stated. Glassware was oven-dried at 100 °C for 12 hours for moisture-sensitive reactions. Reactions were carried out under Argon using anhydrous solvents. Room temperature refers to ambient temperature. The reactions were monitored by thin layer chromatography (TLC) on aluminum-supported silica gel and visualized by exposure to 240-nm UV light and/or exposure to basic phosphomolybdic acid solution followed by heating. Flash column chromatography was performed with Merck PLC Silica Gel 60 using commercial solvents. All in vacuo evaporations were conducted at reduced pressure using a Büchi rotary evaporator.

Infrared spectra were recorded on a PerkinElmer Spectrum Two FTIR, 10.03.06 version, in KBr disks. Maximum absorption ( $\nu$ ) are reported in wavenumbers (cm<sup>-1</sup>). GC-MS was performed on a Hewlett-Packard MSD 5973 instrument equipped with a fused silica column with 5% phenylmethyl polysiloxane (HP-5MS, 30 m, 0.25 mm, film thickness 0.25  $\mu$ m). The initial analysis temperature was 250 °C, which was increased at 5 °C/min until reaching the final temperature of 300 °C and reported as  $m/z$ . NMR spectroscopy (<sup>1</sup>H, <sup>13</sup>C, APT, COSY, HSQC, HMBC) was recorded at 25 °C with a Bruker-Advance Neo 400 (<sup>1</sup>H at 400 MHz and <sup>13</sup>C at 100 MHz) in deuterated solvents, CDCl<sub>3</sub>. NMR chemical shifts ( $\delta$ ) are quoted in parts per million (ppm) referencing the residual proton or the carbon peak of the solvent (CDCl<sub>3</sub>:  $\delta_H = 7.26$  and  $\delta_C = 77.1$ ). The coupling constants are reported in hertz (Hz). Data for <sup>1</sup>H spectra are presented as chemical shift ( $\delta$ , ppm), integration and multiplicity ( $b$ , broad;  $s$ , singlet;  $d$ , doublet;  $t$ , triplet;  $q$ , quartet;  $quin$ , quintet;  $sept$ , septet;  $m$ , multiplet; or as a combination (e.g.,  $dd$ ,  $dt$ , etc.)). All carbon spectra were obtained by the attached proton test (APT).

### 2.2. Synthesis

*Ent*-kaur-3-acetoxy-15-ene (1) was allowed to react with an excess of LiAlH<sub>4</sub>, as a result of which the hydroxyl derivative was obtained (2), and different derivatives were synthesized from it: one derivative by oxidation of this hydroxyl group (3) and the rest were acetoxy-alkylated derivatives (4-8) by esterification reactions with different organic acids. The synthetic pathway of these *ent*-kaurene derivatives is represented in Scheme 1.

*Ent*-kaur-3-acetoxy-15-ene (1) [23] was allowed to react with an excess of LiAlH<sub>4</sub>, as a result of which the hydroxyl derivative was obtained (2) and its different derivatives were synthesized: one derivative by oxidation of this hydroxyl group (3), and the rest were acetoxy-alkylated derivatives (4-8) by esterification reactions with different organic acids. The results of the research on the synthesis, characterization, and antimicrobial activity against some microorganisms of novel *ent*-kaurane-type diterpenoid derivatives are presented here.


#### 2.2.1. Synthesis of *ent*-kaur-3-hydroxy-15-ene (2) derivative

2.44 mmol of *ent*-kaur-3-acetoxy-15-ene (1) were introduced into a round bottom flask under an argon atmosphere and afterward dissolved in 160 mL of diethyl ether. Subsequently, an excess of LiAlH<sub>4</sub> (26.31 mmol), was added and it was left under continuous stirring in an argon atmosphere at room temperature for 8 h. Subsequently, the sample was carefully treated with a 1 M HCl solution until the appearance of a white precipitate. The mixture was filtered and the aqueous phase was extracted several times with diethyl ether (3 × 30 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuum. As a result, a white solid was obtained, which was purified by column chromatography using a mixture of hexane:AcOEt (4:1) as an eluent to obtain compound 2.

*Ent*-kaur-3-hydroxy-15-ene (2): Color: White crystals. Yield: 792.00 mg, 99 %. M.p.: 127-129 °C. FT-IR (KBr,  $\nu$ , cm<sup>-1</sup>): 3392 (O-H, alcohol), 3040 (=C-H, alkene), 2925 (C-H), 1656 (C=C, alkene), 1045 (C-O, alcohol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>,  $\delta$ , ppm): 5.06 ( $s$ , 1H, CH, H<sub>15</sub>), 3.57 ( $s$ , 1H, OH, H<sub>21</sub>), 3.15 ( $m$ , 1H, CH-OH, H<sub>3</sub>), 1.86 ( $m$ , 1H, CH, H<sub>13</sub>), 1.80 ( $s$ , 3H, CH<sub>3</sub>, H<sub>17</sub>), 1.56 ( $m$ , 2H, CH<sub>2</sub>, H<sub>1</sub>), 1.54 ( $t$ , 2H, CH<sub>2</sub>, H<sub>2</sub>), 1.49 ( $m$ , 2H, CH<sub>2</sub>, H<sub>6</sub>), 1.48 ( $m$ , 2H, CH<sub>2</sub>, H<sub>12</sub>), 1.47 ( $m$ , 1H, CH, H<sub>5</sub>), 1.43 ( $m$ , 2H, CH<sub>2</sub>, H<sub>11</sub>), 1.33 ( $t$ , 2H, CH<sub>2</sub>, H<sub>14</sub>), 1.29 ( $m$ , 2H, CH<sub>2</sub>, H<sub>7</sub>), 0.82 ( $s$ , 3H, CH<sub>3</sub>, H<sub>18</sub>), 0.80 ( $s$ , 3H, CH<sub>3</sub>, H<sub>19</sub>), 0.78 ( $m$ , 1H, CH, H<sub>9</sub>), 0.73 ( $s$ , 3H, CH<sub>3</sub>, H<sub>20</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>,  $\delta$ , ppm): 139.78 (C, C<sub>16</sub>), 124.47 (CH, C<sub>15</sub>), 79.06 (CH-OH, C<sub>3</sub>), 55.41 (CH, C<sub>5</sub>), 52.40 (CH, C<sub>9</sub>), 47.79 (CH, C<sub>13</sub>), 41.68 (C, C<sub>8</sub>), 41.49 (CH<sub>2</sub>, C<sub>14</sub>), 39.68 (C, C<sub>10</sub>), 37.86 (C, C<sub>4</sub>), 33.01 (CH<sub>2</sub>, C<sub>6</sub>), 32.69 (CH<sub>2</sub>, C<sub>7</sub>), 31.27 (CH<sub>2</sub>, C<sub>1</sub>), 28.22 (CH<sub>3</sub>, C<sub>18</sub>), 27.28 (CH<sub>2</sub>, C<sub>2</sub>), 26.75 (CH<sub>2</sub>, C<sub>12</sub>), 23.37 (CH<sub>3</sub>, C<sub>17</sub>), 22.70 (CH<sub>3</sub>, C<sub>19</sub>), 21.07 (CH<sub>2</sub>, C<sub>11</sub>), 17.66 (CH<sub>3</sub>, C<sub>20</sub>). MS (EI,  $m/z$  (%)): 288 (M<sup>+</sup>, 15.0), 273.2 (M<sup>+</sup>-CH<sub>3</sub>, 40.2), 271.2 (M<sup>+</sup>-OH, 38.1), 218.1 (M<sup>+</sup>-C<sub>5</sub>H<sub>11</sub>, 80.7), 189.2 (M<sup>+</sup>-C<sub>6</sub>H<sub>10</sub>O, 33.2), 161.2 (M<sup>+</sup>-C<sub>8</sub>H<sub>15</sub>O, 29.4).

#### 2.2.2. Synthesis of *ent*-kaur-3-oxo-15-ene (3) derivative

An equivalent of compound 2 (0.25 mmol) was dissolved in 10 mL of tetrahydrofuran (THF) and 4 equivalents of stabilized 2-iodoxybenzoic acid (SIBX) (1.01 mmol). The reaction mixture was continuously stirred in an argon atmosphere at room temperature for 48 hours. The mixture obtained was washed with water and extracted several times with diethyl ether (3 × 30 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuum. The crude product was purified through silica gel using hexane:AcOEt (99:1) as an eluent to give compound 3.

Scheme 1. Synthetic pathway of *ent*-kaurene derivatives.

*Ent*-kaur-3-oxo-15-ene (**3**): Color: White crystalline solid. Yield: 72.00 mg, 98 %. M.p.: 131-132 °C. FT-IR (KBr,  $\nu$ ,  $\text{cm}^{-1}$ ): 3041 (=C-H, alkene), 2927 (C-H), 1709 (C=O, ketone), 1639 (C=C, alkene).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm): 0.79 (*m*, 1H, CH, H<sub>9</sub>), 0.81 (*s*, 3H, CH<sub>3</sub>, H<sub>20</sub>), 1.06 (*s*, 3H, CH<sub>3</sub>, H<sub>19</sub>), 1.08 (*s*, 3H, CH<sub>3</sub>, H<sub>18</sub>), 1.26 (*s*, 1H, CH, H<sub>5</sub>), 1.28 (*m*, 2H, CH<sub>2</sub>, H<sub>7</sub>), 1.34 (*t*, 2H, CH<sub>2</sub>, H<sub>14</sub>), 1.43 (*m*, 2H, CH<sub>2</sub>, H<sub>11</sub>), 1.48 (*m*, 2H, CH<sub>2</sub>, H<sub>12</sub>), 1.49 (*m*, 2H, CH<sub>2</sub>, H<sub>6</sub>), 1.58 (*m*, 2H, CH<sub>2</sub>, H<sub>1</sub>), 1.90 (*s*, 3H, CH<sub>3</sub>, H<sub>17</sub>), 1.97 (*s*, 1H, CH, H<sub>13</sub>), 2.71 (*t*, 2H, CH<sub>2</sub>, H<sub>2</sub>), 5.16 (*s*, 1H, CH, H<sub>15</sub>).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm): 216.86 (C=O, C<sub>3</sub>), 139.87 (C, C<sub>16</sub>), 124.34 (CH, C<sub>15</sub>), 55.40 (CH, C<sub>9</sub>), 52.54 (CH, C<sub>5</sub>), 48.05 (CH, C<sub>13</sub>), 47.58 (C, C<sub>4</sub>), 41.69 (C, C<sub>8</sub>), 39.72 (CH<sub>2</sub>, C<sub>14</sub>), 37.68 (C, C<sub>10</sub>), 35.72 (CH<sub>2</sub>, C<sub>7</sub>), 34.37 (CH<sub>2</sub>, C<sub>2</sub>), 33.58 (CH<sub>2</sub>, C<sub>1</sub>), 28.16 (CH<sub>3</sub>, C<sub>18</sub>), 26.89 (CH<sub>2</sub>, C<sub>12</sub>), 23.33 (CH<sub>3</sub>, C<sub>17</sub>), 21.67 (CH<sub>2</sub>, C<sub>6</sub>), 20.92 (CH<sub>3</sub>, C<sub>19</sub>), 19.79 (CH<sub>2</sub>, C<sub>11</sub>), 17.63 (CH<sub>3</sub>, C<sub>20</sub>). MS (EI, *m/z* (%)): 286 (M<sup>+</sup>, 15.11), 257.2 (M<sup>+</sup>-C<sub>2</sub>H<sub>6</sub>, 40.2), 247.2 (M<sup>+</sup>-C<sub>3</sub>H<sub>4</sub>, 38.1), 218.2 (M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>, 38.6), 189.2 (M<sup>+</sup>-C<sub>6</sub>H<sub>10</sub>O, 69.4).

### 2.2.3. Synthesis of *ent*-kaur-3-acetoxyalkylated derivatives (**4-8**)

A compound **2** equivalent was placed in a round bottom flask and dissolved in 10 mL of  $\text{CH}_2\text{Cl}_2$ , with 1.5 equivalents of 3,4-bis(benzyloxy)-caffeic acid (0.52 mmol), 3 equivalents of dicyclohexylcarbodiimide (DCC, 1.04 mmol) and 3 equivalents of *N,N*-dimethylaminopyridine (DMAP, 1.04 mmol). The reaction mixture was left stirring at room temperature for 48 hours under an atmosphere of argon, while being continuously monitored by TLC. The resulting mixture was washed with

water and extracted with  $\text{CH}_2\text{Cl}_2$  (3 x 20 mL). The organic phase was dried with  $\text{MgSO}_4$ , filtered, and concentrated. The crude was purified through silica gel using hexane:AcOEt (96:4) as eluent, yielding compound **4**: Color: solid white crystalline. Yield: 143.40 mg, 47.80 %. M.p.: 130-131 °C. A similar procedure was performed for the synthesis of compounds **5-8**, maintaining the same conditions and the purification procedure described above. For compound **5**: 1 equiv. compound **2** was dissolved in 5 mL of  $\text{CH}_2\text{Cl}_2$ , with 3 equiv. of *p*-bromophenylacetic acid (0.939 mmol), 3 equiv. DCC, and 3 equiv. DMAP. Color: white. Yield: 40.00 mg, 45 %. M.p.: 145-146 °C. Compound **6**: 1 equiv. compound **2** was dissolved in 10 mL of  $\text{CH}_2\text{Cl}_2$ , with 6 equiv. of succinic acid (2.08 mmol), 5 equiv. DCC, and 5 equiv. DMAP. Color: white. Yield: 57.00 mg, 57 %. M.p.: 185-186 °C. Compound **7**: 2 equiv. compound **2** (0.35 mmol) was dissolved in 10 mL of  $\text{CH}_2\text{Cl}_2$ , with 1 equiv. of succinic acid (0.17 mmol), 3 equiv. DCC, and 3 equiv. DMAP. Color: white. Yield: 49.00 mg, 50 %. M.p.: 190-191 °C. Compound **8**: 1 equiv. compound **2** was dissolved in 10 mL of  $\text{CH}_2\text{Cl}_2$ , with 4 equiv. of kaurenic acid (1.04 mmol), 6 equiv. DCC (1.04 mmol), and 6 equiv. DMAP (1.04 mmol). Color: white. Yield: 140.00 mg, 40 %. M.p.: 173 -174 °C. The synthetic pathway and structure of the compounds are given below (Scheme 1).

*Ent*-kaur-3-O-(6',7'-bibenzyl-oxy-caffeoyl)-15-ene (**4**): FT-IR (KBr,  $\nu$ ,  $\text{cm}^{-1}$ ): 3090 (=C-H, alkene), 2946 (C-H), 1702 (C=O, ester carbonyl), 1633 (C=C, alkene), 1261 (C-O, ester), 843 (=C-H, alkene).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm): 0.73 (*s*, 3H, CH<sub>3</sub>, H<sub>20</sub>), 0.79 (*m*, 1H, CH, H<sub>9</sub>), 0.80 (*s*, 3H, CH<sub>3</sub>, H<sub>19</sub>), 0.81 (*s*, 3H, CH<sub>3</sub>, H<sub>18</sub>), 1.30 (*m*, 2H, CH<sub>2</sub>, H<sub>7</sub>), 1.34 (*t*, 2H, CH<sub>2</sub>, H<sub>14</sub>), 1.43 (*m*, 2H,

CH<sub>2</sub>, H<sub>11</sub>), 1.47 (m, 2H, CH<sub>2</sub>, H<sub>12</sub>), 1.48 (m, 2H, CH<sub>2</sub>, H<sub>2</sub>), 1.50 (m, 2H, CH<sub>2</sub>, H<sub>6</sub>), 1.51 (m, 1H, CH, H<sub>5</sub>), 1.55 (m, 2H, CH<sub>2</sub>, H<sub>1</sub>), 1.83 (s, 3H, CH<sub>3</sub>, H<sub>17</sub>), 1.87 (s, 1H, CH, H<sub>13</sub>), 4.66 (t, 1H, CH-COO, H<sub>3</sub>), 5.16 (s, 1H, CH, H<sub>15</sub>), 5.21 (s, 2H, -O-CH<sub>2</sub>-Ar, H<sub>1'</sub>), 5.22 (s, 2H, -O-CH<sub>2</sub>-Ar, H<sub>1''</sub>), 6.26 (d, 1H, -CH=CH-COO-, H<sub>2</sub>), 6.93 (s, 1H, -CH=CH-Ar, H<sub>9</sub>), 6.95 (s, 1H, -CH=CH-Ar, H<sub>8</sub>), 7.16 (s, 1H, -CH=CH-Ar, H<sub>5</sub>), 7.35 (m, 2H, 2CH-Ar, H<sub>5'</sub>), 7.40 (m, 2H, 2CH-Ar, H<sub>4'</sub>), 7.41 (m, 2H, 2CH-Ar, H<sub>6'</sub>), 7.44 (m, 2H, 2CH-Ar, H<sub>7'</sub>), 7.45 (m, 2H, 2CH-Ar, H<sub>3'</sub>), 7.56 (d, 1H, -CH=CH-COO-, H<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, δ, ppm): 167.15 (-COO, C<sub>1</sub>), 151.03 (-C=C, C<sub>7</sub>), 149.10 (-C=C, C<sub>6</sub>), 144.12 (=CH, C<sub>3</sub>), 139.78 (=C-CH<sub>3</sub>, C<sub>16</sub>), 136.91 (2C, C<sub>2'</sub>), 128.71 (2CH, C<sub>3'</sub>), 128.70 (2C, C<sub>7'</sub>), 128.19 (-C=C, C<sub>4</sub>), 128.09 (2C, C<sub>6'</sub>), 127.48 (2C, C<sub>5'</sub>), 127.32 (2CH, C<sub>4'</sub>), 124.35 (CH=CH, C<sub>15</sub>), 122.98 (=CH, C<sub>5</sub>), 117.01 (=CH-, C<sub>2</sub>), 114.40 (=CH, C<sub>9</sub>), 113.81 (-C=C, C<sub>8</sub>), 80.84 (CH-COO, C<sub>3</sub>), 71.49 (CH<sub>2</sub>-O, C<sub>1'</sub>), 71.11 (CH<sub>2</sub>-O, C<sub>1''</sub>), 55.44 (CH, C<sub>9</sub>), 52.50 (CH, C<sub>5</sub>), 48.02 (CH, C<sub>13</sub>), 40.18 (C, C<sub>8</sub>), 39.85 (C, C<sub>10</sub>), 39.67 (CH<sub>2</sub>, C<sub>14</sub>), 38.11 (C, C<sub>4</sub>), 36.60 (CH<sub>2</sub>, C<sub>7</sub>), 33.00 (CH<sub>2</sub>, C<sub>1</sub>), 28.16 (CH<sub>3</sub>, C<sub>18</sub>), 26.66 (CH<sub>2</sub>, C<sub>12</sub>), 23.57 (CH<sub>2</sub>, C<sub>2</sub>), 23.41 (=C-CH<sub>3</sub>, C<sub>17</sub>), 22.70 (CH<sub>3</sub>, C<sub>19</sub>), 21.10 (CH<sub>2</sub>, C<sub>6</sub>), 18.47 (CH<sub>2</sub>, C<sub>11</sub>), 17.66 (CH<sub>3</sub>, C<sub>20</sub>). MS (EI, m/z (%)): 341.2 (M<sup>+</sup>-C<sub>20</sub>H<sub>18</sub>O<sub>2</sub>, 15.11), 289.1 (M<sup>+</sup>-C<sub>26</sub>H<sub>41</sub>O<sub>2</sub>, 10.21), 218.5 (M<sup>+</sup>-C<sub>7</sub>H<sub>10</sub>O<sub>2</sub>, 68.5), 189.2 (M<sup>+</sup>-C<sub>9</sub>H<sub>14</sub>O<sub>2</sub>, 38.6).

**Ent-kaur-3-O-(carboxymethyl-2'-p-bromophenyl)-15-ene (5):** FT-IR (KBr, ν, cm<sup>-1</sup>): 3036 (=C-H, alkene), 2924 (C-H), 1733 (C=O, ester carbonyl), 1659 (C=C, alkene), 1255 (C-O, ester), 1136 (Ar-Br), 804 (p-Ar-H). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ, ppm): 0.76 (s, 3H, CH<sub>3</sub>, H<sub>20</sub>), 0.78 (m, 1H, CH, H<sub>9</sub>), 0.80 (s, 3H, CH<sub>3</sub>, H<sub>19</sub>), 0.81 (s, 3H, CH<sub>3</sub>, H<sub>18</sub>), 1.32 (m, 2H, CH<sub>2</sub>, H<sub>7</sub>), 1.35 (t, 2H, CH<sub>2</sub>, H<sub>14</sub>), 1.44 (m, 2H, CH<sub>2</sub>, H<sub>11</sub>), 1.47 (m, 2H, CH<sub>2</sub>, H<sub>2</sub>), 1.48 (m, 2H, CH<sub>2</sub>, H<sub>12</sub>), 1.51 (m, 1H, CH, H<sub>5</sub>), 1.52 (m, 2H, CH<sub>2</sub>, H<sub>6</sub>), 1.53 (m, 2H, CH<sub>2</sub>, H<sub>1</sub>), 1.91 (s, 3H, CH<sub>3</sub>, H<sub>17</sub>), 1.98 (m, 1H, CH, H<sub>13</sub>), 3.59 (s, 2H, CH, H<sub>5</sub>), 4.51 (t, 1H, CH-COO, H<sub>3</sub>), 5.13 (s, 1H, CH, H<sub>15</sub>), 7.20 (d, 2H, -CH<sub>2</sub>-COO, H<sub>2</sub>), 7.45 (d, 2H, =CH-, H<sub>4</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, δ, ppm): 170.89 (COO, C<sub>1</sub>), 139.78 (=C, C<sub>16</sub>), 133.53 (C-CH<sub>2</sub>-COO, C<sub>3</sub>), 131.73 (2CH-, C<sub>5</sub>), 131.17 (2CH-, C<sub>4</sub>), 124.42 (=CH-, C<sub>15</sub>), 121.13 (Br-CH=, C<sub>6</sub>), 81.56 (CH-COO, C<sub>3</sub>), 55.36 (CH, C<sub>9</sub>), 52.51 (CH, C<sub>5</sub>), 47.75 (CH, C<sub>13</sub>), 41.52 (Ar-CH<sub>2</sub>-COO, C<sub>2</sub>), 40.18 (C, C<sub>8</sub>), 39.67 (CH<sub>2</sub>, C<sub>14</sub>), 38.52 (C, C<sub>10</sub>), 37.94 (C, C<sub>4</sub>), 35.65 (CH<sub>2</sub>, C<sub>7</sub>), 32.97 (CH<sub>2</sub>, C<sub>1</sub>), 28.16 (CH<sub>3</sub>, C<sub>18</sub>), 26.65 (CH<sub>2</sub>, C<sub>12</sub>), 23.67 (CH<sub>2</sub>, C<sub>2</sub>), 23.38 (CH<sub>3</sub>-C=, C<sub>17</sub>), 21.42 (CH<sub>3</sub>, C<sub>19</sub>), 21.01 (CH<sub>2</sub>, C<sub>6</sub>), 18.40 (CH<sub>2</sub>, C<sub>11</sub>), 17.65 (CH<sub>3</sub>, C<sub>20</sub>). MS (EI, m/z (%)): 405.2 (M<sup>+</sup>-Br, 18.2), 367.2 (M<sup>+</sup>-C<sub>3</sub>H<sub>4</sub>Br, 25.3), 297.2 (M<sup>+</sup>-CH<sub>5</sub>OBr, 47.2), 218.2 (M<sup>+</sup>-C<sub>5</sub>H<sub>11</sub>Br, 80.5), 189.2 (M<sup>+</sup>-C<sub>14</sub>H<sub>18</sub>O<sub>2</sub>Br, 48.7).

**Ent-kaur-3-O-succinyl-15-ene (6):** FT-IR (KBr, ν, cm<sup>-1</sup>): 3368 (-O-H, carboxylic acid), 3036 (=C-H, alkene), 2943 (C-H), 1710 (C=O, carboxylic acid carbonyl), 1719 (-O-C=O, ester carbonyl), 1637 (C=C, alkene), 1378 (C-O), 1082 (C-O), 843 (=C-H). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ, ppm): 0.73 (s, 3H, CH<sub>3</sub>, H<sub>20</sub>), 0.79 (m, 1H, CH, H<sub>9</sub>), 0.80 (s, 3H, CH<sub>3</sub>, H<sub>19</sub>), 0.81 (s, 3H, CH<sub>3</sub>, H<sub>18</sub>), 1.33 (m, 2H, CH<sub>2</sub>, H<sub>7</sub>), 1.34 (t, 2H, CH<sub>2</sub>, H<sub>14</sub>), 1.45 (m, 2H, CH<sub>2</sub>, H<sub>11</sub>), 1.46 (m, 2H, CH<sub>2</sub>, H<sub>2</sub>), 1.49 (m, 2H, CH<sub>2</sub>, H<sub>12</sub>), 1.51 (m, 2H, CH<sub>2</sub>, H<sub>6</sub>), 1.53 (m, 1H, CH, H<sub>5</sub>), 1.54 (m, 2H, CH<sub>2</sub>, H<sub>1</sub>), 1.83 (s, 3H, CH<sub>3</sub>-C=, H<sub>17</sub>), 1.86 (s, 1H, CH, H<sub>13</sub>), 2.57 (t, 2H, CH<sub>2</sub>-COO, H<sub>2</sub>), 2.61 (t, 2H, CH<sub>2</sub>-COOH, H<sub>3</sub>), 4.47 (t, 1H, CH-COO, H<sub>3</sub>), 5.05 (s, 1H, -CH=, H<sub>15</sub>), 11.4 (s, 1H, H-OOC, H<sub>4</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, δ, ppm): 177.94 (COOH, C<sub>4</sub>), 171.96 (COO, C<sub>1</sub>), 139.77 (=C-, C<sub>16</sub>), 124.42 (=CH-, C<sub>15</sub>), 81.72 (CH-COO, C<sub>3</sub>), 55.40 (CH, C<sub>9</sub>), 52.50 (CH, C<sub>5</sub>), 47.75 (CH, C<sub>13</sub>), 40.15 (C, C<sub>8</sub>), 9.67 (CH<sub>2</sub>, C<sub>14</sub>), 38.55 (C, C<sub>10</sub>), 37.90 (C, C<sub>4</sub>), 35.68 (CH<sub>2</sub>, C<sub>7</sub>), 32.97 (CH<sub>2</sub>, C<sub>1</sub>), 29.46 (CH<sub>2</sub>-COO, C<sub>2</sub>), 29.15 (CH<sub>2</sub>-COOH, C<sub>3</sub>), 28.15 (CH<sub>3</sub>, C<sub>18</sub>), 26.64 (CH<sub>2</sub>, C<sub>12</sub>), 23.65 (CH<sub>2</sub>, C<sub>2</sub>), 23.35 (CH<sub>3</sub>-C=, C<sub>17</sub>), 21.55 (CH<sub>3</sub>, C<sub>19</sub>), 21.06 (CH<sub>2</sub>, C<sub>6</sub>), 18.36 (CH<sub>2</sub>, C<sub>11</sub>), 17.66 (CH<sub>3</sub>, C<sub>20</sub>). MS (EI, m/z (%)): 388 (M<sup>+</sup>, 17.7), 342.2 (M<sup>+</sup>-HCOOH, 19.3), 218.2 (M<sup>+</sup>-C<sub>8</sub>H<sub>13</sub>O<sub>3</sub>, 89.6), 189.2 (M<sup>+</sup>-C<sub>9</sub>H<sub>14</sub>O<sub>2</sub>, 40.6), 161.0 (M<sup>+</sup>-C<sub>8</sub>H<sub>16</sub>O<sub>2</sub>, 18.4), 147.2 (M<sup>+</sup>-C<sub>9</sub>H<sub>18</sub>O<sub>2</sub>, 30.4).

**Di-ent-kaur-3,3'-O-succinyl-15,15'-diene (7):** FT-IR (KBr, ν, cm<sup>-1</sup>): 2993 (=C-H, alkene), 2944 (C-H), 1731 (-O-C=O, ester carbonyl), 1631 (C=C, alkene), 1133 (C-O), 836 (=C-H). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ, ppm): 0.73 (s, 6H, 2CH<sub>3</sub>, H<sub>20</sub>), 0.79 (m, 2H, 2CH, H<sub>9</sub>), 0.80 (s, 6H, 2CH<sub>3</sub>, H<sub>19</sub>), 0.81 (s, 6H, 2CH<sub>3</sub>, H<sub>18</sub>), 1.33 (m,

4H, 2CH<sub>2</sub>, H<sub>7</sub>), 1.35 (m, 4H, 2CH<sub>2</sub>, H<sub>14</sub>), 1.44 (m, 4H, 2CH<sub>2</sub>, H<sub>11</sub>), 1.47 (m, 4H, 2CH<sub>2</sub>, H<sub>12</sub>), 1.48 (m, 4H, 2CH<sub>2</sub>, H<sub>2</sub>), 1.51 (m, 4H, 2CH<sub>2</sub>, H<sub>6</sub>), 1.52 (m, 2H, 2CH, H<sub>5</sub>), 1.54 (m, 4H, 2CH<sub>2</sub>, H<sub>1</sub>), 1.82 (s, 6H, 2CH<sub>3</sub>, H<sub>17</sub>), 1.88 (s, 2H, 2CH, H<sub>13</sub>), 2.57 (s, 4H, 2CH<sub>2</sub>, H<sub>2'</sub>), 4.47 (t, 2H, 2CH, H<sub>3</sub>), 5.05 (s, 2H, 2CH=, H<sub>15</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, δ, ppm): 172.16 (2COO, C<sub>1</sub>), 139.78 (2C=, C<sub>16</sub>), 124.46 (2CH=, C<sub>15</sub>), 81.37 (2CH, C<sub>3</sub>), 55.40 (2CH, C<sub>9</sub>), 52.51 (2CH, C<sub>5</sub>), 47.99 (2CH, C<sub>13</sub>), 40.17 (2C, C<sub>8</sub>), 39.67 (2CH<sub>2</sub>, C<sub>14</sub>), 38.58 (2C, C<sub>10</sub>), 37.94 (2C, C<sub>4</sub>), 35.68 (2CH<sub>2</sub>, C<sub>7</sub>), 33.00 (2CH<sub>2</sub>, C<sub>1</sub>), 29.80 (2CH<sub>2</sub>, C<sub>2</sub>), 28.16 (2CH<sub>3</sub>, C<sub>18</sub>), 26.63 (2CH<sub>2</sub>, C<sub>12</sub>), 23.57 (2CH<sub>2</sub>, C<sub>2</sub>), 23.38 (2CH<sub>3</sub>, C<sub>17</sub>), 21.55 (2CH<sub>3</sub>, C<sub>19</sub>), 21.06 (2CH<sub>2</sub>, C<sub>6</sub>), 18.38 (2CH<sub>2</sub>, C<sub>11</sub>), 17.66 (2CH<sub>3</sub>, C<sub>20</sub>). MS (EI, m/z (%)): 468 (M<sup>+</sup>-C<sub>14</sub>H<sub>21</sub>, 34.6), 426.2 (M<sup>+</sup>-C<sub>17</sub>H<sub>27</sub>, 35.5), 342.2 (M<sup>+</sup>-C<sub>21</sub>H<sub>30</sub>O<sub>2</sub>, 40.7), 327.2 (M<sup>+</sup>-C<sub>22</sub>H<sub>33</sub>O<sub>2</sub>, 39.3).

**Ent-kaurenic anhydride (8):** FT-IR (KBr, ν, cm<sup>-1</sup>): 3069 (=C-H, alkene), 2934 (C-H), 1789 (-O-C=O, asymmetric vibration of ester carbonyl), 1729 (-O-C=O, symmetric vibration of ester carbonyl), 1657 (C=C, alkene), 1378 (C-O, anhydride), 887 (=C-H). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ, ppm): 0.73 (s, 6H, 2CH<sub>3</sub>, H<sub>20</sub>), 0.78 (m, 2H, 2CH, H<sub>9</sub>), 0.80 (s, 6H, 2CH<sub>3</sub>, H<sub>18</sub>), 0.83 a<sup>β</sup>(axi) x 2 - 1.95 b<sup>α</sup>(equi) x 2 (m, 4H, 2CH<sub>2</sub>, H<sub>1</sub>), 1.11 (d, 2H, 2CH, H<sub>5</sub>), 1.30 (m, 4H, 2CH<sub>2</sub>, H<sub>7</sub>), 1.40 (m, 4H, 2CH<sub>2</sub>, H<sub>11</sub>), 1.41 (m, 4H, 2CH<sub>2</sub>, H<sub>2</sub>), 1.50 (m, 4H, 2CH<sub>2</sub>, H<sub>6</sub>), 1.59 (m, 4H, 2CH<sub>2</sub>, H<sub>12</sub>), 2.05 (m, 4H, 2CH<sub>2</sub>, H<sub>15</sub>), 2.08 (m, 4H, 2CH<sub>2</sub>, H<sub>14</sub>), 2.19 (m, 4H, 2CH<sub>2</sub>, H<sub>3</sub>), 2.64 (s, 2H, 2CH, H<sub>13</sub>), 4.74 H<sub>a</sub> x 2 - 4.80 H<sub>b</sub> x 2 (s, 4H, 2=CH, H<sub>17</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, δ, ppm): 173.55 (2COO-, C<sub>19</sub>), 155.77 (2C=CH<sub>2</sub>, C<sub>16</sub>), 103.10 (2CH<sub>2</sub>=C, C<sub>17</sub>), 57.27 (2CH, C<sub>5</sub>), 54.98 (2CH, C<sub>9</sub>), 48.92 (2CH<sub>2</sub>, C<sub>15</sub>), 45.39 (2C-COO-, C<sub>4</sub>), 43.96 (2CH, C<sub>13</sub>), 43.78 (2C, C<sub>8</sub>), 41.31 (2CH<sub>2</sub>, C<sub>1</sub>), 41.30 (2CH<sub>2</sub>, C<sub>14</sub>), 40.60 (2CH<sub>2</sub>, C<sub>7</sub>), 39.60 (2C, C<sub>10</sub>), 33.10 (2CH<sub>2</sub>, C<sub>12</sub>), 33.00 (2CH<sub>2</sub>, C<sub>3</sub>), 28.06 (2CH<sub>3</sub>, C<sub>18</sub>), 21.92 (2CH<sub>2</sub>, C<sub>6</sub>), 18.97 (2CH<sub>2</sub>, C<sub>2</sub>), 18.44 (2CH, C<sub>11</sub>), 16.40 (2CH<sub>3</sub>, C<sub>20</sub>). MS (EI, m/z (%)): 256.2 (M<sup>+</sup>-C<sub>21</sub>H<sub>30</sub>O<sub>3</sub>, 37.6), 241.2 (M<sup>+</sup>-C<sub>22</sub>H<sub>33</sub>O<sub>3</sub>, 39.9), 157.0 (M<sup>+</sup>-C<sub>28</sub>H<sub>45</sub>O<sub>3</sub>, 10.6).

### 2.3. Antibacterial activity

Antibacterial activity was determined using the paper-disk-diffusion agar method [24,25]. The following microorganisms were tested: *Staphylococcus aureus* (ATCC 25923), *Enterococcus faecalis* (ATCC 29212), *Klebsiella pneumoniae* (ATCC 23357), *Escherichia coli* (ATCC 25922) and *Pseudomonas aeruginosa* (ATCC 27853). An 18-hour culture of each microorganism in 2.5 mL of Mueller-Hinton (MH) broth at 37 °C was used. The bacterial inoculum was adjusted with physiological saline solution to the Mc Farland turbidity standard N ° 0.5 (1 × 10<sup>8</sup> CFU/mL). Each inoculum was spread with a swab on the surface of a plate containing Mueller-Hinton agar and then a filter paper disk (6 mm diameter) previously impregnated with 10 µL of the compound dissolved in DMSO at a concentration of 2 mg/mL for each (1, 2, 3, 4, 5, 6, 7, 8) was placed on the surface. A disc impregnated with DMSO was included as a negative control. Furthermore, the standard disc of the reference antibiotic was placed as a positive control for each microorganism (Oxacillin® 1 µg for *Staphylococcus aureus*; Vancomycin® 30 µg for *Enterococcus faecalis*; Tobramycin® 10 µg for *Escherichia coli*; Aztreonam® 30 µg for *Klebsiella pneumoniae*; Cefepime® 30 µg for *Pseudomonas aeruginosa*). After placing the discs on the Petri plates, they were refrigerated at 4 °C for 24 h [24]. Inhibition halos were read at 24 h and measured (mm) around the disc. All tests were performed in duplicate. The measurement of inhibition halos for antibacterial activity was done as follows: C = A - B (C = Size of the inhibition halo; A = Size of the halo plus the disk of filter paper; B = Size of the filter paper disk, 6 mm).

### 2.4. Antifungal activity

Antifungal activity was determined by the paper-disk-diffusion agar method [24]. The microorganism tested was *Candida krusei* (ATCC 6558), using Fluconazole 100 µg as a

positive control, and dimethylsulfoxide (DMSO) as a negative control. The strain had been repacked 12 hours before it came to a salted dextrose agar and it was used to prepare the inoculum which was compared to the Mc Farland Turbidity Standard N° 1.5 ( $10^8$  CFU/mL). Each inoculum was spread with a swab on the surface of a plate containing Mueller-Hinton agar and then 6 mm diameter holes were opened in it, where 20  $\mu$ L of the compounds dissolved in DMSO were placed at a 2 mg/mL concentration for each one (1, 2, 3, 4, 5, 6, 7, 8). One well with DMSO was included as a negative control and one well with the reference antibiotic as a positive control. The Petri plates were then refrigerated at 4 °C for 24 h [26]. Inhibition halos were read at 24 h and measured (mm) around the well. All tests were performed in duplicate.

### 3. Results and discussion

#### 3.1. Chemistry

In recent decades, the introduction of ester functional groups into organic compounds has become increasingly common in drug design and development, as ester substitution can greatly improve the solubility, bioavailability, and absorption of drugs [27]. In this context, previous studies on the biological activity of *ent*-kaurene-type diterpenoids and triterpenes reported that the presence of oxygenated groups such as hydroxyls or esters on the C-3 carbon of the *ent*-kaurene core, as well as in triterpenes (whose core is largely constituted by a decahydronaphthalene ring, such as the *ent*-kaurene core with rings A and B), increases biological activity [28-30]. Therefore, in this study, structural modifications were performed on the carbon C-3 of the *ent*-kaurene core of compound 1 (Scheme 1) by introducing different oxygenated groups, especially esters, to investigate the structure-activity relationship (SAR) of the derivatives *ent*-kaur-3-acetoxyalkylated and further enhance their antimicrobial power. The structure of the synthesized derivatives was characterized by IR,  $^1$ H NMR,  $^{13}$ C NMR, and GC-MS.

The natural product *ent*-kaur-3-acetoxy-15-ene (1) was first subjected to a reduction reaction of the acetate group using  $\text{LiAlH}_4$ , forming the C3-hydroxylated derivative *ent*-kaur-3-hydroxy-15-ene (2). FT-IR analysis showed evidence of this transformation by the appearance of a characteristic absorption band of alcohol ( $3392\text{ cm}^{-1}$ , O-H) and the disappearance of the characteristic absorption bands of the ester group [ $1735\text{ cm}^{-1}$  (O-C=O) and  $1243\text{ cm}^{-1}$  (O-C)] [23]. In the  $^1$ H NMR spectrum, the disappearance of the singlet of the methyl protons of the ester group at  $\delta$  1.98 ppm and the appearance of a small singlet at  $\delta$  3.57 ppm of the proton of a secondary hydroxyl group, as well as the high-field shift of the signal coming from the  $\text{H}_3$  methine proton at  $\delta$  3.15 ppm is mainly observed compared to compound 1. The  $^{13}$ C NMR spectrum confirms the presence of 20 carbons, mainly the disappearance of the carbonyl signal of the ester group at  $\delta$  171.17 ppm is observed, together with the methyl signal of the same terminal ester at  $\delta$  21.47 ppm, both signals belonging to the starting compound (1) [23], and the shift to a high field of the methine carbon at  $\delta$  79.06 ppm. On the other hand, its mass spectrum showed the molecular ion peak at  $m/z$  288 [M $^+$ ] consistent with their molecular formula with five unsaturations.

The derivative 3, *ent*-kaur-3-oxo-15-ene, was obtained through an oxidation reaction of the hydroxyl group of compound 2 using SIBX as an oxidizing agent. FT-IR showed the characteristic band of the carbonyl group at  $1709\text{ cm}^{-1}$ , which is an absent band compared to the IR spectrum of compound 2, as well as the disappearance of the hydroxyl group signal. In the  $^1$ H NMR spectrum, the multiplet corresponding to the methyne proton  $\text{H}_3$  at  $\delta$  3.15 ppm disappears compared to the  $^1$ H NMR of 2, as well as the small downfield singlet of the hydroxyl group at  $\delta$  3.57 ppm. The low-field shift of the  $\text{H}_2$  methylene proton

signal at  $\delta$  2.71 ppm is also notable, which is due to the effective oxidation of the hydroxyl group to carbonyl. The  $^{13}$ C NMR spectrum confirms the presence of 20 carbons, mainly showing the shift to the low field of carbon  $\text{C}_3$  at  $\delta$  216.86 ppm with respect to compound 2, as well as an increase in the  $\delta$  of methylene  $\text{C}_2$  at  $\delta$  34.37 ppm and the carbon quaternary  $\text{C}_4$  at  $\delta$  47.58 ppm. The GC-MS study showed the molecular ion peak at  $m/z$  286 [M $^+$ ] consistent with their molecular formula with six unsaturations.

Acetoxy-alkylated derivatives (4-8) were obtained by Steglich Esterification between compound 2 and variation of different carboxylic acids (Scheme 1), using DCC as reaction activator and DMAP as catalyst. In view of the FT-IR spectra, the absence of the peak corresponding to -OH and the appearance of two characteristic absorption bands in the range of  $1730\text{--}1740\text{ cm}^{-1}$  (O-C=O) and  $1300\text{--}1000\text{ cm}^{-1}$  (C-O) indicated that compound 2 (alcohol) had been converted into products (esters). Specifically, derivative 4 shows a smaller absorption shift compared to the carbonyl band ( $1702\text{ cm}^{-1}$ , CO-C=C-) due to being conjugated, and a more intense band corresponding to the alkene group stands out ( $1633\text{ cm}^{-1}$ , C=C). For derivative 5, in addition to the presence of bands of the ester group at  $1733\text{ cm}^{-1}$  (O-C=O) and  $1255\text{ cm}^{-1}$  (C-O), a band at  $1136\text{ cm}^{-1}$  characteristic of the halogen-aromatic ring bond (Br-Ar) is also shown, and at  $804\text{ cm}^{-1}$  the band indicates the *para* disposition of this halogen on the aromatic ring. In derivative 6, the presence of a carboxyl group is confirmed by observing a characteristic broad absorption band of the O-H bond at  $3368\text{ cm}^{-1}$  and a characteristic carbonyl band at  $1710\text{ cm}^{-1}$ , as well as the presence of ester group bands at  $1719\text{ cm}^{-1}$  (O-C=O),  $1378\text{ cm}^{-1}$  (C-O, tension vibration) and  $1082\text{ cm}^{-1}$  (C-O, bending vibration). Compound 7 showed bands of the ester group at  $1731\text{ cm}^{-1}$  (O-C=O) and  $1133\text{ cm}^{-1}$  (C-O); and in derivative 8, the presence of characteristic bands of the anhydride group at  $1789\text{ cm}^{-1}$  (>C=O, asymmetric vibration),  $1729\text{ cm}^{-1}$  (>C=O, symmetric vibration) and  $1378\text{ cm}^{-1}$  (C-O of anhydride) stands out, confirming the formation of this functional group in the structure.

Concerning the  $^1$ H NMR spectrum, the downfield shift of the  $\text{H}_3$  proton in compounds 4-8 in contrast to compound 2 confirms the transformation of the OH group. Derivative 4 showed the  $\text{H}_3$  signal at  $\delta$  4.66 ppm, two singlets at  $\delta$  5.22 ppm and 5.21 ppm attributed to the methylene protons  $\text{H}_{1'}$  and  $\text{H}_{1''}$ , respectively, and two doublets at  $\delta$  6.26 ppm and  $\delta$  7.56 ppm corresponding to the methine protons  $\text{H}_2$  and  $\text{H}_3$ , respectively, which lie on the conjugated C=C double bond; a set of signals corresponding to the aromatic rings of the 3,4-bibenzyloxy-caffeoyl system are also observed. Compound 5 showed the methyne  $\text{H}_3$  signal at  $\delta$  4.51 ppm, a singlet signal at  $\delta$  3.59 ppm attributed to the methylene protons  $\text{H}_2$ , and two doublets are observed at  $\delta$  7.20 ppm and  $\delta$  7.45 ppm at a low field, attributed to the phenyl protons  $\text{H}_4$  and  $\text{H}_5$ , respectively. Compound 6 exhibited the methyne  $\text{H}_3$  signal at  $\delta$  4.47 ppm, and two strong triplets at  $\delta$  2.57 ppm and  $\delta$  2.61 ppm attributed to the methylene protons  $\text{H}_2$  and  $\text{H}_3$ , respectively, corresponding to the alkyl part of succinic acid. The derivative 7 displayed the methyne  $\text{H}_3$  signal at  $\delta$  4.47 ppm, and an intense singlet at  $\delta$  2.57 ppm attributed to the methylene protons  $\text{H}_2$  and  $\text{H}_2''$ , which exhibit a single signal due to molecular symmetry. The proton spectrum of compound 8 differs mainly from compound 2 in the following: the  $\text{H}_{13}$  methine proton is at  $\delta$  2.64 ppm;  $\text{H}_3$  proton is a doublet and is at  $\delta$  2.19 ppm; the vinyl proton  $\text{H}_{15}$  singlet disappears at  $\delta$  5.06 ppm and is now found at  $\delta$  2.05 ppm as a multiplet; the signal of the  $\text{H}_{19}$  methyl protons disappears;  $\text{H}_{17}$  protons are diastereotopic and show two singlets at  $\delta_{a17}$  4.74 ppm and  $\delta_{b17}$  4.80 ppm. These results reveal that the esterification reaction between compound 2 and *ent*-kaurenic acid did not take place; in contrast, the  $^1$ H NMR spectrum of this product is consistent with the  $^1$ H NMR spectrum of *ent*-kaurenic acid [31].

**Table 1.** Antibacterial activity of compound **1** and its synthetic derivatives (**2-8**) expressed as diameters of the inhibition halo (mm) #.

Bacterial strains	Compounds								Positive control				
	1	2	3	4	5	6	7	8	OX	VA	TO	AZ	CF
<i>Staphylococcus aureus</i>	IA	10	IA	16	IA	IA	11	IA	*23	–	–	–	–
<i>Enterococcus faecalis</i>	IA	10	12	12	8	10	10	IA	–	*19	–	–	–
<i>Escherichia coli</i>	8	IA	10	13	8	IA	10	IA	–	–	*26	–	–
<i>Klebsiella pneumoniae</i>	10	8	10	10	8	8	10	8	–	–	–	*34	–
<i>Pseudomonas aeruginosa</i>	8	10	8	8	10	10	10	10	–	–	–	–	*32

# IA: inactive; OX: Oxacillin®; VA: Vancomycin®; TO: Tobramycin®; AZ: Aztreonam®; CF: Cefepime®.

\* Halo of inhibition in mm for the positive control groups [24,25].

**Table 2.** Antifungal activity of compound **1** and its synthetic derivatives (**2-8**) expressed as inhibition halo diameters (mm) #.

Fungal strains	Compounds								Positive control
	1	2	3	4	5	6	7	8	FLU (100 µg)
<i>Candida krusei</i>	8	10	IA	12	IA	10	8	IA	*15

# IA: inactive; FLU: Fluconazole®.

\* Halo of inhibition in mm for the control groups [26].

The assignment of  $^{13}\text{C}$  NMR spectra of carbon atoms presented in these acetoxy-alkylated derivatives showed the following. Compound **4** contains 43 carbons, highlighting the presence of two signals at  $\delta$  71.49 ppm and  $\delta$  71.11 ppm corresponding to the carbons of the methylenes  $\text{C}_{1''}$  and  $\text{C}_{1''}$ , respectively; two signals at  $\delta$  144.12 ppm and  $\delta$  117.12 ppm corresponding to the carbons that make up the conjugated double bond  $\text{C}_{3'}$  and  $\text{C}_{2'}$ , respectively; ester formation is confirmed when the signal corresponding to the quaternary carbon  $\text{C}_{1'}$  ( $\delta$  167.15 ppm,  $>\text{C}=\text{O}$ ) is observed in the low field; and a set of signals that are consistent with the carbons that make up the aromatic rings of the 3,4-bibenzyloxy-caffeoyl system. The mass spectrum confirms the structure by showing two abundant ions at  $m/z$  341.2 ( $\text{M}^+-\text{C}_{20}\text{H}_{18}\text{O}_2$ ) and  $m/z$  289.1 ( $\text{M}^+-\text{C}_{26}\text{H}_{41}\text{O}_2$ ), which correspond to the breaking of the molecule in half. In derivative **5**, the presence of 28 carbons is confirmed, emphasizing the presence of two signals at  $\delta$  121.13 ppm and  $\delta$  133.53 ppm corresponding to the quaternary carbons  $\text{C}_{3'}$  and  $\text{C}_{6'}$ , respectively, and two signals at  $\delta$  131, 17 ppm and  $\delta$  131.73 ppm corresponding to the  $\text{C}_{4'}$  and  $\text{C}_{5'}$  carbons, respectively; which make up the aromatic ring from *p*-bromophenylacetic acid; in addition, ester formation is confirmed by observing the signal corresponding to the  $\text{C}_{1'}$  carbonyl carbon ( $\delta$  170.89 ppm,  $>\text{C}=\text{O}$ ) in the low field. The mass spectrum confirms the structure by showing an abundant ion at  $m/z$  405.2 ( $\text{M}^+-\text{Br}$ ).

The presence of 24 carbons is confirmed in compound **6**; the presence in a high field of two signals at  $\delta$  29.46 ppm and  $\delta$  29.15 ppm stands out with respect to  $\text{C}_{2'}$  and  $\text{C}_{3'}$  methylenes, respectively; and the two signals at  $\delta$  171.96 ppm and  $\delta$  177.94 ppm attributed to the  $\text{C}_{1'}$  carbonyl carbon of the ester group and the  $\text{C}_{4'}$  carboxylic carbon, respectively, confirming the presence of both functional groups in the structure of this derivative. The mass spectrum confirms the structure showing the molecular ion peak at  $m/z$  388.2 [ $\text{M}^+$ ] consistent with their molecular formula with seven unsaturations. Compound **7** highlights 22 carbon signs, showing the presence of a signal at  $\delta$  29.80 ppm at a high field corresponding to methylenes  $\text{C}_{2'}$ , and at a low field, a signal at  $\delta$  172.16 ppm corresponding to the carbonyl carbons  $\text{C}_{1'}$  of the ester group. The mass spectrum demonstrates the formation of a dimeric structure by showing three abundant ions at  $m/z$  468 ( $\text{M}^+-\text{C}_{14}\text{H}_{21}$ , 34.6), 426.2 ( $\text{M}^+-\text{C}_{17}\text{H}_{27}$ , 35.5), and 342.2 ( $\text{M}^+-\text{C}_{21}\text{H}_{30}\text{O}_2$ , 40.7), consistent with their molecular formula with twelve unsaturation. Compound **8** presents quantifiable signals for 19 carbons, highlighting:  $\text{C}_3$  signal at  $\delta$  33.00 ppm,  $\text{C}_{15}$  carbon at  $\delta$  48.92 ppm,  $\text{C}_{16}$  at  $\delta$  155.77 ppm,  $\text{C}_{17}$  at  $\delta$  103.10 ppm, and  $\text{C}_{19}$  at  $\delta$  173.55 ppm, which is found at  $\delta$  184.72 ppm in  $^{13}\text{C}$  NMR spectrum of *ent*-kaurenic acid [30]. The similarity of these data with those reported in the bibliography for  $^{13}\text{C}$  NMR of *ent*-kaurenic acid [32], and also the displacement obtained from the  $\text{C}_{19}$  signal indicate that this carboxylic acid reacted with itself, forming a symmetrical anhydride (dimer). This is confirmed with the mass spectrum,

where three abundant ions are shown at  $m/z$  256.2 ( $\text{M}^+-\text{C}_{21}\text{H}_{30}\text{O}_3$ , 37.6),  $m/z$  241.2 ( $\text{M}^+-\text{C}_{22}\text{H}_{33}\text{O}_3$ , 39.9), and  $m/z$  157.0 ( $\text{M}^+-\text{C}_{28}\text{H}_{45}\text{O}_3$ , 10.6), consistent with their molecular formula with twelve unsaturation. The formation of this collateral product could be explained by the steric hindrance exerted by the bulky structure of *ent*-kaurenic acid on the alkoxide (also bulky) formed from compound **2**, which is a weaker nucleophile than the carboxylate formed from the same acid. Therefore, the formation of the anhydride occurs. According to Steglich *et al.*, when poor nucleophiles are used in Steglich esterification, side product formation prevails [33].

### 3.2. Antimicrobial activity

In this study, the antibacterial activity of the synthetic derivatives of compound **1** (**2-8**) was evaluated using the disk diffusion method (Kirby-Bauer). The results obtained are summarized in Table 1 and are expressed as the diameters of the inhibition halo reported in millimeters.

The synthesized compounds evaluated showed specific antibacterial activity against some bacteria used. Compounds **4** and **7** showed antibacterial activity by generating inhibition halos against all tested, compound **4** being the one generating the highest inhibition halos (*Staphylococcus aureus*: 16 mm; *Enterococcus faecalis*: 12 mm; *Escherichia coli*: 13 mm; *Klebsiella pneumoniae*: 10 mm and *Pseudomonas aeruginosa*: 8 mm). Compound **2** was found to be inactive only against *Escherichia coli*, while compounds **3**, **5**, **6**, and **8** were found to be inactive only against *Staphylococcus aureus*. Finally, compound **6** was found to be active against *Enterococcus faecalis* (10 mm), *Klebsiella pneumoniae* (8 mm), and *Pseudomonas aeruginosa* (10 mm). However, the antifungal activity of the synthetic derivatives was also evaluated through the well diffusion method on Müller-Hinton agar (Kirby-Bauer). The results obtained are summarized in Table 2 and are expressed as the diameters of the inhibition halo reported in millimeters.

Some of the synthetic compounds evaluated showed specific antifungal activity against *Candida krusei*. Compounds **2**: 10 mm, **4**: 12 mm, **6**: 10 mm, and **7**: 8 mm were active, compound **4** being the most active of all (12 mm). On the contrary, compounds **3**, **5**, and **8** did not present inhibition halos.

These results of antimicrobial activity reveal a notable relationship between the structural modification of the  $\text{C}_3$  carbon of the *ent*-kaurene core and the activity, which, in general terms, is an improvement. Previous studies on the structure-activity relationship of *ent*-kaurenes have identified that the pharmacological action of these compounds is based on the perhydrophenanthrene unit (rings A, B, and C) fused with a cyclopentane unit (ring D) formed by a bridge of two carbons between  $\text{C}_8$  and  $\text{C}_{13}$  (Figure 1), this skeleton confers lipophilic properties that are essential to cross membranes and occupy

hydrophobic pockets in the target cell [34]. In addition, various authors describe some specific structural requirements for the biological activity of *ent*-kaurenes and terpenes based on a decalin ring: 1) a substituted decalin system, capable of inserting itself into a lipophilic region of the cell membrane, and 2) a hydrophilic or relatively hydrophilic fragment that contains a hydrogen bond donor or acceptor group capable of interacting with acceptor or donor groups in the membrane (mostly phosphorylated groups), as an "anchoring" group; this way, these compounds will have the ability to cross the phospholipid membrane and cause cell damage to the microorganism [35,36].

In this regard, the synthetic *ent*-kaurenes tested in this work present structural characteristics very similar to those described above: the substituted perhydrophenanthrene unit is fused with a cyclopentane unit, which makes them possess an essential lipophilic character to cross the cell membrane. However, each compound possesses distinctive characteristics: compounds **4**, **5**, **6**, and **7** have ester groups in C<sub>3</sub> whose hydrophilicity is low; however, they present a well-defined negative dipole moment in the carbonyl oxygen atom that allows them to accept hydrogen bonds (anchor group) with the hydrophilic part of the membrane phospholipids. In addition, each of these compounds has acidic protons or another reactive system that also allow them to interact with the hydrophilic portion of membrane phospholipids. Compound **4**, aside from having five acidic protons (H<sub>3</sub>, H<sub>2</sub>, H<sub>3</sub>, H<sub>1'</sub>, and H<sub>1''</sub>), also shows an  $\alpha,\beta$ -unsaturated system whose reactivity is very high and causes electron donor or acceptor dipole moments that are highly defined, making the compound more susceptible to form hydrogen bonds with the phosphorylated groups of the cell membrane. This could be the reason why this compound turned out to be the most active against all of the microorganisms tested.

Unlike the others, compound **2** has a hydroxyl group in C<sub>3</sub>, which is a hydrophilic group that donates hydrogen bonds responsible for "anchoring" with the phosphorylated hydrogen bond acceptor groups of the cell membrane. On the contrary, compound **3** has a ketone in C<sub>3</sub>, which is a non-polar functional group that confers lipophilicity to the molecule; however, it has a negative dipole moment defined by the oxygen atom, which allows it to be an acceptor of hydrogen bonds with the hydrophilic part of the phospholipids, and it anchors itself to the cell membrane and exerts antibacterial activity. Finally, compound **8** turned out to be slightly active against bacteria and inactive against the fungus, possibly due to the high lipophilicity of the molecule conferred by the two *ent*-kaurene core. According to Urzua *et al.*, the high addition of alkyl moieties to the decalinic system causes a decrease in biological activity due to excess lipophilicity that hinders molecular anchorage with the hydrophilic part of phospholipids [33].

#### 4. Conclusion

A series of seven new *ent*-kaurene-type diterpenes was synthesized from the new natural product *ent*-kaur-3-acetoxy-15-ene (**1**). Structural elucidation was performed using FT-IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, and GC-MS spectra. The synthesized compounds were evaluated for their antibacterial and antifungal activities and showed specific activity against some bacterial and fungal strains. *Ent*-kaur-3-*O*-(6',7'-bibenzyl-oxycafeoyl)-15-ene (**4**) exhibited the higher antibacterial activity against all microorganisms tested: *Staphylococcus aureus* (16 mm), *Enterococcus faecalis* (12 mm), *Escherichia coli* (13 mm), *Klebsiella pneumoniae* (10 mm), *Pseudomonas aeruginosa* (8 mm) and *Candida krusei* (10 mm). These results reveal a remarkable structure-activity relationship on the C<sub>3</sub> carbon of the *ent*-kaurene core, where the presence of oxygenated groups such as hydroxyl or alkyl esters enhances activity. However, this activity will depend (aside from the fundamental decalin

system) on the type and number of hydrophilic or relatively hydrophilic fragments on C<sub>3</sub> containing a hydrogen bond donor or acceptor group capable of interacting with acceptor or donor groups in the phospholipid cell membrane, as an "anchor" group, traversing and causing cell damage to the microorganism.

#### Acknowledgements

All authors thank the Research Institute 'Dr. Alfredo Nicolás Usubillaga del Hierro', Faculty of Pharmacy and Bioanalysis, University of Los Andes, Mérida 5101, Venezuela for its support. The Research Institute authors are grateful to Prof. Freddy Ramos from the Department of Chemistry, Faculty of Science, National University of Colombia, Bogotá, 111321, Colombia, for NMR and MS equipment. Also, all authors are grateful to the MSc. Ana Deixy Flores from the Clinical Institute 'Santa Filomena', Microbiology Laboratory, Mérida 5101, Venezuela, for antimicrobial assays.

#### Disclosure statement

Conflict of interests: The authors declare that they have no conflict of interest. Ethical approval: All ethical guidelines have been adhered. Sample availability: Samples of the compounds are available from the author.

#### CRedit authorship contribution statement

Conceptualization: Andrés Eduardo Márquez, Alida Pérez Colmenares, Luis Rojas Fermín, Rosa Aparicio, Alfredo Usubillaga; Methodology: Andrés Eduardo Márquez, Alida Pérez, Luis Rojas, Rosa Aparicio; Software: Andrés Eduardo Márquez, Alida Pérez, Freddy Ramos, Rosa Aparicio; Validation: Andrés Eduardo Márquez, Alida Pérez, Rosa Aparicio, Freddy Ramos; Formal Analysis: Andrés Eduardo Márquez, Alida Pérez, Rosa Aparicio, Freddy Ramos; Investigation: Andrés Eduardo Márquez, Alida Pérez, Rosa Aparicio; Resources: Andrés Eduardo Márquez, Alida Pérez, Freddy Ramos, Rosa Aparicio; Data Curation: Andrés Eduardo Márquez, Alida Pérez; Writing - Original Draft: Andrés Eduardo Márquez, Alida Pérez, Rosa Aparicio; Writing - Review and Editing: Andrés Eduardo Márquez, Alida Pérez, Rosa Aparicio, Ysbelia Obregón; Visualization: Andrés Eduardo Márquez, Alida Pérez, Rosa Aparicio, Ysbelia Obregón; Supervision: Alida Pérez, Luis Rojas, Rosa Aparicio.

#### Funding

Program for the Support of Research Groups (ADG) of the Council of Scientific, Humanistic, Technological, and Artistic Development. University of Los Andes, Mérida, Venezuela. Research Group: Natural Products and Medicinal Chemistry. Research Institute - Natural Products Section.

#### ORCID and Email

Andrés Eduardo Márquez-Chacón

 [andresmqch@gmail.com](mailto:andresmqch@gmail.com)

 <https://orcid.org/0000-0002-8529-505X>

Alida Pérez Colmenares

 [alidaperezc@gmail.com](mailto:alidaperezc@gmail.com)

 <https://orcid.org/0000-0001-8910-4663>

Luis Rojas Fermín

 [rojasfermin33@gmail.com](mailto:rojasfermin33@gmail.com)

 <https://orcid.org/0000-0003-4508-1927>

Rosa Aparicio

 [apariciorosa12@gmail.com](mailto:apariciorosa12@gmail.com)

 <https://orcid.org/0000-0002-5020-0954>

Freddy Alejandro Ramos

 [faramosr@unal.edu.co](mailto:faramosr@unal.edu.co)

 <https://orcid.org/0000-0002-9271-7193>

Alfredo Usubillaga

 [usubi80@gmail.com](mailto:usubi80@gmail.com)

 <https://orcid.org/0000-0002-2913-5684>

Ysbelia Obregón

 [ysbeliaobregon@gmail.com](mailto:ysbeliaobregon@gmail.com)

 <https://orcid.org/0000-0001-6152-6696>

#### References

- [1]. Atanasov, A. G.; the International Natural Product Sciences Taskforce; Zotchev, S. B.; Dirsch, V. M.; Supuran, C. T. Natural products in drug

- discovery: advances and opportunities. *Nat. Rev. Drug Discov.* **2021**, *20*, 200–216.
- [2]. Abdel-Razek, A. S.; El-Naggar, M. E.; Allam, A.; Morsy, O. M.; Othman, S. I. Microbial natural products in drug discovery. *Processes (Basel)* **2020**, *8*, 470.
- [3]. Porto, T. S.; Simão, M. R.; Carlos, L. Z.; Martins, C. H. G.; Furtado, N. A. J. C.; Said, S.; Arakawa, N. S.; dos Santos, R. A.; Veneziani, R. C. S.; Ambrósio, S. R. Pimarane-type diterpenes obtained by biotransformation: Antimicrobial properties against clinically isolated gram-positive multidrug-resistant bacteria. *Phytother. Res.* **2013**, *27*, 1502–1507.
- [4]. Miron-Lopez, G.; Bazzocchi, I. L.; Jimenez-Diaz, I. A.; Moujir, L. M.; Quijano-Quifones, R.; Quijano, L.; Mena-Rejon, G. J. Cytotoxic diterpenes from roots of *Crossopetalum gaumeri*, a Celastraceae species from Yucatan Peninsula. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 2105–2109.
- [5]. Bou, D. D.; Tempone, A. G.; Pinto, É. G.; Lago, J. H. G.; Sartorelli, P. Antiparasitic activity and effect of casearins isolated from *Casearia sylvestris* on *Leishmania* and *Trypanosoma cruzi* plasma membrane. *Phytomedicine* **2014**, *21*, 676–681.
- [6]. Pardo-Vargas, A.; Ramos, F. A.; Cirne-Santos, C. C.; Stephens, P. R.; Paixão, I. C. P.; Teixeira, V. L.; Castellanos, L. Semi-synthesis of oxygenated dolabellane diterpenes with highly in vitro anti-HIV-1 activity. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 4381–4383.
- [7]. Jiang, K.; Chen, L.-L.; Wang, S.-F.; Wang, Y.; Li, Y.; Gao, K. Anti-inflammatory Terpenoids from the Leaves and Twigs of *Dysoxylum gotadhora*. *J. Nat. Prod.* **2015**, *78*, 1037–1044.
- [8]. de S. Vargas, F.; D. O. de Almeida, P.; Aranha, E.; de A. Boleti, A.; Newton, P.; de Vasconcelos, M.; Junior, V.; Lima, E. Biological Activities and Cytotoxicity of Diterpenes from *Copaifera* spp. Oleoresins. *Molecules* **2015**, *20*, 6194–6210.
- [9]. Miranda, M. M.; Panis, C.; da Silva, S. S.; Macri, J. A.; Kawakami, N. Y.; Hayashida, T. H.; Madeira, T. B.; Acquaro, V. R.; Nixdorf, S. L.; Pizzatti, L.; Ambrósio, S. R.; Cecchini, R.; Arakawa, N. S.; Verri, W. A.; Conchon Costa, I.; Pavanelli, W. R. Kaurenoic acid possesses leishmanicidal activity by triggering a NLRP12/IL-1 $\beta$ /cNOS/NO pathway. *Mediators Inflamm.* **2015**, *2015*, 1–10.
- [10]. Zhu, L.; Huang, S.-H.; Yu, J.; Hong, R. Constructive innovation of approaching bicyclo[3.2.1]octane in ent-kauranoids. *Tetrahedron Lett.* **2015**, *56*, 23–31.
- [11]. Usubillaga, A.; Romero, M.; Aparicio, R. Kaurenic acid in Espeletinae. *Acta Hort.* **2003**, 129–130.
- [12]. Aparicio Z., R. L.; Villasmil, T.; Peña, A.; Rojas S., J. C.; Usubillaga, A. Estudio fitoquímico de las hojas de *Espeletia semiglobulata* Cuatrec. *Revista de la Facultad de Farmacia* **2014**, *55*(2), 2–5, <http://www.saber.ula.ve/handle/123456789/38474> (accessed Oct 10, 2023).
- [13]. de Andrade, B. B.; Moreira, M. R.; Ambrosio, S. R.; Furtado, N. A. J. C.; Cunha, W. R.; Heleno, V. C. G.; Silva, A. N.; Simão, M. R.; da Rocha, E. M. P.; Martins, C. H. G.; Veneziani, R. C. S. Evaluation of ent-kaurenoic acid derivatives for their anticarcinogenic activity. *Nat. Prod. Commun.* **2011**, *6*(6), 1934578X1100600.
- [14]. Batista, R.; García, P. A.; Castro, M. A.; Miguel del Corral, J. M.; Speziali, N. L.; de P. Varotti, F.; de Paula, R. C.; García-Fernández, L. F.; Francesch, A.; San Feliciano, A.; de Oliveira, A. B. Synthesis, cytotoxicity and antiplasmodial activity of novel ent-kaurane derivatives. *Eur. J. Med. Chem.* **2013**, *62*, 168–176.
- [15]. Matos, P.; Mahoney, B.; Chan, Y.; Day, D.; Cabral, M.; Martins, C.; Santos, R.; Bastos, J.; Page, P.; Heleno, V. New non-toxic semi-synthetic derivatives from natural diterpenes displaying anti-tuberculosis activity. *Molecules* **2015**, *20*, 18264–18278.
- [16]. Silva, A.; Soares, A. C.; Cabral, M.; de Andrade, A.; da Silva, M.; Martins, C.; Veneziani, R.; Ambrósio, S.; Bastos, J.; Heleno, V. Antitubercular Activity Increase in Labdane Diterpenes from *Copaifera* Oleoresin through Structural Modification. *J. Braz. Chem. Soc.* **2016**, *28*(6), 1106–1112, <http://dx.doi.org/10.21577/0103-5053.20160268> (accessed Oct 10, 2023).
- [17]. Cordero de Rojas, Y.; Lucena de Ustáriz, M. E.; Araujo, L.; Usubillaga, A.; Rojas, L. B.; Moujir, L. Actividad antibacteriana de diterpenos del kaurano aislados de *Coespeletia moritziana* (Sch. Bip. ex Wedd.) Cuatrec. *Revista de la Facultad de Farmacia* **2017**, *59*(2), 03–07, <http://www.saber.ula.ve/handle/123456789/45132> (accessed Oct 10, 2023).
- [18]. Rios Tesch, N. N.; Villalobos Osorio, D. C.; Rojas, L. B.; Aparicio Z., R. L.; Usubillaga, A.; Mitaine Offer, A. C.; Lacaille Dubois, M. A.; Denis, D.; Peixoto, P.; Laurent, P.; Stéphane, Q. In vivo anti-inflammatory activity of grandifloreonic acid and kaurenic acid isolated from *Coespeletia moritziana* and *Espeletia semiglobulata*. *Revista de la Facultad de Farmacia* **2017**, *59* (1), 17–21, <http://www.saber.ula.ve/handle/123456789/44160> (accessed Oct 10, 2023).
- [19]. Villasmil, T.; Rojas, J.; Aparicio, R.; Gamboa, N.; Acosta, M. E.; Rodrigues, J.; Usubillaga, A. Antimalarial activity of some kaurenes. *Nat. Prod. Commun.* **2017**, *12*, 1934578X1701200.
- [20]. Peña, A.; Usubillaga, A.; Alarcón Pineda, L. del V.; Velasco Carrillo, J.; Aparicio Z., R. L. Obtención de derivados azufrados del ácido kaurénico y de otros kaurenos substituidos en la posición C-15 y su actividad antibacteriana. *Revista de la Facultad de Farmacia* **2016**, *57* (1), 3–8, <http://www.saber.ula.ve/handle/123456789/41936> (accessed Oct 10, 2023).
- [21]. Ruiz, Y.; Rodríguez, J.; Arvelo, F.; Usubillaga, A.; Monsalve, M.; Diez, N.; Galindo-Castro, I. Cytotoxic and apoptosis-inducing effect of ent-15-oxo-kaur-16-en-19-oic acid, a derivative of grandiflorolic acid from *Espeletia schultzei*. *Phytochemistry* **2008**, *69*, 432–438.
- [22]. Mora, A. J.; Delgado, G. E.; Vaughan, G. B. M.; Martin, P.; Visbal, T.; Usubillaga, A. A peracetylated glucosyl ester of kaurenic acid. *Acta Crystallogr. Sect. E Struct. Rep. Online* **2004**, *60*, o334–o336.
- [23]. Márquez, A. E.; Pérez, A.; Rojas, L.; Aparicio, R.; Ramos, F.; Obregón, Y.; Usubillaga, A. A New ent-kaurene Diterpenoid Isolated from Leaves of *Espeletia semiglobulata* Cuatrec. and its Potential Antimicrobial Activity. *Biol. Med. Nat. Prod. Chem.* **2023**, *12*, 151–157.
- [24]. CLSI: *Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement*; Clinical & Laboratory Standards Institute, 2013.
- [25]. Wikler, M. A. *Performance standards for antimicrobial disk susceptibility tests; Approved standard*; 11th ed.; Clinical & Laboratory Standards Institute, 2012.
- [26]. Berkow, E. L.; Lockhart, S. R.; Ostrosky-Zeichner, L. Antifungal susceptibility testing: Current approaches. *Clin. Microbiol. Rev.* **2020**, *33*, e00069-19.
- [27]. Abualhasan, M. N.; Al-Masri, M. Y.; Manasara, R.; Yadak, L.; Abu-Hasan, N. S. Anti-inflammatory and anticoagulant activities of synthesized NSAID prodrug esters. *Scientifica (Cairo)* **2020**, *2020*, 1–6.
- [28]. Ohkoshi, E.; Kamo, S.; Makino, M.; Fujimoto, Y. ent-Kaurenoic acids from *Mikania hirsutissima* (Compositae). *Phytochemistry* **2004**, *65*, 885–890.
- [29]. Rodríguez, S.; Garda, H. A.; Heinzen, H.; Moyna, P. Effect of plant monofunctional pentacyclic triterpenes on the dynamic and structural properties of dipalmitoylphosphatidylcholine bilayers. *Chem. Phys. Lipids* **1997**, *89*, 119–130.
- [30]. Herrera, M.; Rodríguez-Rodríguez, R.; Ruiz-Gutiérrez, V. Functional properties of pentacyclic triterpenes contained in “orujo” Olive oil. *Curr. Nutr. Food Sci.* **2006**, *2*, 45–49.
- [31]. Anthonsen, T.; Chantharasakul, S.; Raknes, E.; Sørensen, N. A.; Lindberg, A. A.; Ehrenberg, L. Isolation of ent-16-kauren-19-oic acid and ent-16-kauren-19-ol from *Abrotanella nivigena* Muell. *Acta Chem. Scand.* **1971**, *25*, 1925–1927.
- [32]. Hutchison, M.; Lewer, P.; MacMillan, J. Carbon-13 nuclear magnetic resonance spectra of eighteen derivatives of ent-kaur-16-en-19-oic acid. *J. Chem. Soc., Perkin Trans. 1* **1984**, 2363–2366.
- [33]. Neises, B.; Steglich, W. Simple method for the esterification of carboxylic acids. *Angew. Chem., Int. Ed. Engl.* **1978**, *17*, 522–524.
- [34]. Batista, R.; García, P. A.; Castro, M. A.; Corral, J. M. M. del; Sanz, F.; Speziali, N. L.; Oliveira, A. B. de Methylent-16 $\beta$ ,17-epoxykauran-19-oate. *Acta Crystallogr. Sect. E Struct. Rep. Online* **2007**, *63*, o932–o933.
- [35]. Urzúa, A.; Rezende, M.; Mascayano, C.; Vásquez, L. A structure-activity study of antibacterial diterpenoids. *Molecules* **2008**, *13*, 882–891.
- [36]. Echeverría, J.; Urzúa, A.; Sanhueza, L.; Wilkens, M. Enhanced antibacterial activity of ent-labdane derivatives of salvic acid (7 $\alpha$ -hydroxy-8(17)-ent-labden-15-oic acid): Effect of lipophilicity and the hydrogen bonding role in bacterial membrane interaction. *Molecules* **2017**, *22*, 1039.



Copyright © 2023 by Authors. This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at <http://www.eurjchem.com/index.php/eurjchem/pages/view/terms> and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License (<http://creativecommons.org/licenses/by-nc/4.0>). By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution, or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License (<http://www.eurjchem.com/index.php/eurjchem/pages/view/terms>) are administered by Atlanta Publishing House LLC (European Journal of Chemistry).